Innovent Biologics Doses First Patient in Phase 3 Study of IBI302 for Neovascular AMD
China-based Innovent Biologics, Inc. (HKG: 1801) has announced that the first patient with neovascular age-related...
NHSA Issues Guidelines to Strengthen Medical Insurance Payment Management
The National Healthcare Security Administration (NHSA) has released a set of guiding opinions aimed at...
Sino Medical Sciences’ HT Supreme Stent System Included in French Reimbursement List
Sino Medical Sciences Technology Inc., (SHA: 688108), a leading medical device company based in China,...
HutchMed and Takeda Submit Fruquintinib NDA for Metastatic CRC in Japan
China-based HutchMed (HKG: 0013, NASDAQ: HCM) has announced that its partner Takeda (TYO: 4502) has...
Bio-Thera Solutions’ BAT1806 Receives US FDA Approval as Biosimilar to Actemra/RoActemra
Bio-Thera Solutions Ltd (SHA: 688177), a China-based biopharmaceutical company, announced that its biosimilar version of...
Sichuan Biokin’s IZalontamab Gets US FDA Greenlight for NSCLC Clinical Study
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a China-based pharmaceutical company, has announced that it...
Innovent Biologics Withdraws Parsaclisib Filing in China, Halts Development
Innovent Biologics Inc., a leading China-based biotech company (HKG: 1801), has announced the voluntary withdrawal...
Jiangsu Hengrui Licenses Pyrotinib to Dr. Reddy’s for Indian Market
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has entered into a licensing agreement with...
Beijing Joins Jiangxi’s Interferon Volume-Based Procurement Initiative
The Beijing Municipal Medical Insurance Bureau has announced its participation in the Jiangxi-led interferon inter-provincial...
Sanofi Enters Collaboration with Teva for IBD Drug TEV’574 Development
Sanofi (NASDAQ: SNY) has entered into a collaboration agreement with Teva (NYSE: TEVA) for the...
AstraZeneca Reports Positive Phase III Results for Forxiga in Children with Type 2 Diabetes
UK-based AstraZeneca (AZ, NASDAQ: AZN) has announced promising results from the Phase III T2NOW study...
Sandoz Becomes Independent After Spin-Off from Novartis
Switzerland-based generic and biosimilar drug maker Sandoz (SWX: SDZ) officially became a fully independent company...
Eli Lilly Acquires Point Biopharma to Enhance Oncology Portfolio
Eli Lilly (NYSE: LLY) announced last week its agreement to acquire radiopharmaceutical company Point Biopharma...
Sanofi’s Nexviazyme Approved in China as Enzyme Replacement Therapy for Pompe Disease
Sanofi’s (NASDAQ: SNY) next-generation enzyme replacement therapy (ERT), Nexviazyme (avalglucosidase alfa), has received marketing approval...
NMPA and NHC Tighten Regulations on Etomidate and Modafinil
The National Medical Products Administration (NMPA) and the National Health Commission (NHC) have jointly issued...
Hangzhou HealSun Biopharm Secures RMB 200 Million in Series B+ Financing
Hangzhou HealSun Biopharm Co., Ltd., a Chinese contract research organization (CRO) and contract development and...
Viatris to Divest Women’s Health and API Businesses, Offloading 12 Factories and 6,000 Employees
US-based Viatris Inc. (NASDAQ: VTRS) is set to divest its women’s health business, API operations...
Janssen and Sanofi Partner for Development of First-in-Class E. coli Vaccine
The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) has entered into a strategic...
Takeda Initiates Global Withdrawal of Exkivity Following Phase III Trial Results
Japan-based Takeda (TYO: 4502) has announced the voluntary global withdrawal of its tyrosine kinase inhibitor...
Kyowa Hakko Kirin to Acquire Orchard Therapeutics for $477.6 Million
Japan-based Kyowa Hakko Kirin is poised to acquire UK-headquartered Orchard Therapeutics plc for a total...